RESUMEN
Predictive biomarkers play an important role in our efforts to individualize pharmacotherapy, and within recent years, a number of different types of assays have been introduced. These biomarkers may potentially support the selection and dosage of specific drugs in order to maximize efficacy and minimize adverse reactions in the individual patient. However, in many instances, the scientific and clinical evidence is insufficient to support the prescribing decision. When predictive biomarkers are used to guide pharmacotherapy, it is important to secure that decisions are based on solid clinical evidence. Here, the regulatory authorities, especially the FDA, have been at the forefront in relation to regulate this type of biomarker assay in order to secure patient safety. The approval process for companion diagnostics is an example of this effort, where the scientific validity of the biomarker and assay is in focus. With the approaching implementation of the new IVD Regulation, greater attention will also be paid to analytical and clinical validity of biomarker assays in the EU. For any type of predictive biomarker assay, including pharmacogenetic and tumour profiling tests, the clinical evidence needs to be in place before they are used routinely in the clinic.
Asunto(s)
Bioensayo/instrumentación , Biomarcadores/análisis , Pruebas de Farmacogenómica/instrumentación , Bioensayo/métodos , Bioensayo/normas , Aprobación de Pruebas de Diagnóstico , Unión Europea , Pruebas de Farmacogenómica/métodos , Pruebas de Farmacogenómica/normas , Medicina de Precisión/métodos , Juego de Reactivos para Diagnóstico/normas , Estados Unidos , United States Food and Drug Administration/normasRESUMEN
Interindividual variability in drug efficacy and toxicity is a major challenge in clinical practice. Variations in drug pharmacokinetics (PKs) and pharmacodynamics (PDs) can be, in part, explained by polymorphic variants in genes encoding drug metabolizing enzymes and transporters (absorption, distribution, metabolism, and excretion) or in genes encoding drug receptors. Pharmacogenomics (PGx) has allowed the identification of predictive biomarkers of drug PKs and PDs and the current knowledge of genome-disease and genome-drug interactions offers the opportunity to optimize tailored drug therapy. High-throughput PGx genotyping, from targeted to more comprehensive strategies, allows the identification of PK/PD genotypes to be developed as clinical predictive biomarkers. However, a biomarker needs a robust process of validation followed by clinical-grade assay development and must comply to stringent regulatory guidelines. We here discuss the methodological challenges and the emerging technological tools in PGx biomarker discovery and validation, at the crossroad among molecular genetics, bioinformatics, and clinical medicine.
Asunto(s)
Biomarcadores Farmacológicos/análisis , Farmacogenética/métodos , Investigación Biomédica Traslacional/métodos , Biología Computacional/métodos , Biología Computacional/tendencias , Interacciones Farmacológicas/genética , Estudios de Factibilidad , Estudio de Asociación del Genoma Completo , Técnicas de Genotipaje/instrumentación , Técnicas de Genotipaje/métodos , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Farmacogenética/instrumentación , Farmacogenética/tendencias , Pruebas de Farmacogenómica/instrumentación , Pruebas de Farmacogenómica/métodos , Pruebas de Farmacogenómica/tendencias , Variantes Farmacogenómicas , Investigación Biomédica Traslacional/instrumentación , Investigación Biomédica Traslacional/tendencias , Estudios de Validación como AsuntoAsunto(s)
Legislación de Dispositivos Médicos , Técnicas de Diagnóstico Molecular/métodos , Pruebas de Farmacogenómica/métodos , Medicina de Precisión/métodos , Biomarcadores , Unión Europea , Objetivos , Humanos , Técnicas In Vitro , Legislación de Dispositivos Médicos/organización & administración , Técnicas de Diagnóstico Molecular/instrumentación , Pruebas de Farmacogenómica/instrumentación , Pruebas de Farmacogenómica/legislación & jurisprudencia , Medicina de Precisión/instrumentaciónRESUMEN
The antiplatelet agent clopidogrel, a prodrug that requires bioactivation through the cytochrome P450 2C19 (CYP2C19) enzyme, is commonly prescribed post-percutaneous coronary intervention (PCI). Genetic variation in CYP2C19 contributes to individual variability in clopidogrel response, and can lead to adverse cardiovascular events. Incorporating CYP2C19 testing during routine clinical care helps identify high-risk patients, and provides the opportunity for pharmacotherapeutic interventions in the early post-PCI period. The Spartan RX CYP2C19 System has emerged as an optimal genotyping assay for use in clinical care due to ease of use, utilization of buccal swabs, and rapid turnaround time. However, workflow constraints related to sample collection and processing, storage, time, and personnel were encountered when integrating testing into clinical care. To improve clinical workflow and successfully implement CYP2C19 genotyping at our institution, we validated the Spartan RX System to return genotype utilizing blood samples. Our Molecular Diagnostic Laboratory tested 26 known reference materials and both blood and buccal swab samples from 23 patients and volunteers using the Spartan RX Assay. Genotype results were 100% concordant between DNA from blood and buccal swabs for all patients or volunteers, and consistent with expected results for the 26 reference materials. For reproducibility, three samples were tested in at least four separate runs, with all resulting genotypes in agreement between runs. Post-validation, the laboratory began offering CYP2C19 testing during clinical care. DNA extracted from blood can serve as a genomic DNA source for the Spartan RX Assay. Alteration of the methodology allowed for clinical implementation to support genotype-guided therapy.